JP2021534158A5 - - Google Patents

Info

Publication number
JP2021534158A5
JP2021534158A5 JP2021507737A JP2021507737A JP2021534158A5 JP 2021534158 A5 JP2021534158 A5 JP 2021534158A5 JP 2021507737 A JP2021507737 A JP 2021507737A JP 2021507737 A JP2021507737 A JP 2021507737A JP 2021534158 A5 JP2021534158 A5 JP 2021534158A5
Authority
JP
Japan
Prior art keywords
cancer
independently
substituted
pharmaceutical composition
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021507737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534158A (ja
JP7433291B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046592 external-priority patent/WO2020037092A1/en
Publication of JP2021534158A publication Critical patent/JP2021534158A/ja
Publication of JP2021534158A5 publication Critical patent/JP2021534158A5/ja
Application granted granted Critical
Publication of JP7433291B2 publication Critical patent/JP7433291B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021507737A 2018-08-16 2019-08-15 イミダゾ[4,5-c]キノリン誘導体のNLRP3モジュレーター Active JP7433291B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862764900P 2018-08-16 2018-08-16
US62/764,900 2018-08-16
PCT/US2019/046592 WO2020037092A1 (en) 2018-08-16 2019-08-15 Imidazo[4,5-c]quinoline derived nlrp3-modulators

Publications (3)

Publication Number Publication Date
JP2021534158A JP2021534158A (ja) 2021-12-09
JP2021534158A5 true JP2021534158A5 (cg-RX-API-DMAC7.html) 2022-08-01
JP7433291B2 JP7433291B2 (ja) 2024-02-19

Family

ID=67777458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021507737A Active JP7433291B2 (ja) 2018-08-16 2019-08-15 イミダゾ[4,5-c]キノリン誘導体のNLRP3モジュレーター

Country Status (7)

Country Link
US (1) US12024513B2 (cg-RX-API-DMAC7.html)
EP (1) EP3837015B1 (cg-RX-API-DMAC7.html)
JP (1) JP7433291B2 (cg-RX-API-DMAC7.html)
KR (1) KR102817037B1 (cg-RX-API-DMAC7.html)
CN (1) CN112996567A (cg-RX-API-DMAC7.html)
ES (1) ES2974964T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020037092A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202101486RA (en) 2018-08-16 2021-03-30 Innate Tumor Immunity Inc Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
WO2021142252A1 (en) * 2020-01-10 2021-07-15 Incyte Corporation Tricyclic compounds as inhibitors of kras
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
WO2023283213A1 (en) 2021-07-07 2023-01-12 Incyte Corporation Tricyclic compounds as inhibitors of kras
CA3224841A1 (en) 2021-07-14 2023-01-19 Zhenwu Li Tricyclic compounds as inhibitors of kras
CA3229855A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
US12030884B2 (en) 2021-10-01 2024-07-09 Incyte Corporation Pyrazoloquinoline KRAS inhibitors
KR20240101561A (ko) 2021-10-14 2024-07-02 인사이트 코포레이션 Kras의 저해제로서의 퀴놀린 화합물

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
JP2006513212A (ja) 2002-12-20 2006-04-20 スリーエム イノベイティブ プロパティズ カンパニー アリール/ヘタリール置換されたイミダゾキノリン
US20080015184A1 (en) 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
WO2006009832A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
JP5863058B2 (ja) * 2010-05-17 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 1H−イミダゾ[4,5−c]キノリン
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
US10654807B2 (en) 2013-12-20 2020-05-19 The University Of Kansas Toll-like receptor 8 agonists
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CN108289912A (zh) 2015-09-01 2018-07-17 先天肿瘤免疫公司 具有提高的免疫力或免疫抑制性细胞因子抗性的免疫细胞及其用途
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
RU2722149C1 (ru) * 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
EP3402255B1 (en) 2016-02-02 2021-03-31 Huawei Technologies Co., Ltd. Emission power verification method, user equipment, and base station
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
EP3445761A1 (en) * 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
WO2017184735A1 (en) 2016-04-19 2017-10-26 Ifm Therapeutics, Inc Nlrp3 modulators
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑

Similar Documents

Publication Publication Date Title
JP2021534168A5 (cg-RX-API-DMAC7.html)
JP2021522249A5 (cg-RX-API-DMAC7.html)
JP2020125349A5 (cg-RX-API-DMAC7.html)
JP2020508302A5 (cg-RX-API-DMAC7.html)
Guo et al. Interleukin-6 signaling pathway in targeted therapy for cancer
ES2728739T3 (es) Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada
RU2016108667A (ru) Комбинированная терапия для лечения рака
JP2018510191A5 (cg-RX-API-DMAC7.html)
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
JP2018062523A5 (cg-RX-API-DMAC7.html)
JP2019535746A5 (cg-RX-API-DMAC7.html)
RU2017145026A (ru) Соединение, ингибирующее brk
JP2022500496A5 (cg-RX-API-DMAC7.html)
JP2022517109A5 (cg-RX-API-DMAC7.html)
JP2014528464A5 (cg-RX-API-DMAC7.html)
JP2016528197A5 (cg-RX-API-DMAC7.html)
RU2007140734A (ru) Замещенные гетероциклы и их применение в качестве ингибиторов chki, pdki и pak
RU2015121424A (ru) Комбинированная терапия
JP2023506787A5 (cg-RX-API-DMAC7.html)
JP2016528162A5 (cg-RX-API-DMAC7.html)
JP2015536986A5 (cg-RX-API-DMAC7.html)
JP2024511996A5 (cg-RX-API-DMAC7.html)
JP2014518544A5 (cg-RX-API-DMAC7.html)
RU2020113749A (ru) Аналоги таиланстатина
RU2014154009A (ru) Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания